### Best Pharmaceuticals for Children Act



OMB # 0925- 0643

Expiration Date: 2/28/2021

Public reporting burden for this collection of information is estimated to average 10 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0643). Do not return the completed form to this address.

Thank you for attending the 9th Annual Meeting of T32 Trainees! Please take a few minutes to evaluate this meeting. Our goal is to obtain feedback so that we can improve the next meeting.

Responses are anonymous. As such, we are unable to respond to feedback submitted here. If you would like a response to a comment or question, please email us at <a href="mailto:bpca@infinityconferences.com">bpca@infinityconferences.com</a>.


Please select the choice below that best describes your role at this meeting.

O Pediatric Clinical Pharmacology Fellow
Other Pediatric Fellow
Adult Clinical Pharmacology Fellow
Other Adult Fellow
O Former Fellow
O PI/Program Director
Other (FDA, NIH, etc.)
Other (FDA, NIH, etc.)

## Best Pharmaceuticals for Children Act | Eunice Kennedy Shriver National Institute of Child Health and Human Development |

#### **Virtual Meeting Logistics**

On a scale of 1 to 5 with 5 being best, how would you rate Zoom as the virtual platform for the meeting?



#### Agenda Feedback

Please provide your feedback on the following sessions on August 31:	
1:15-2:00 PM: Fellow Networking Session (leave blank if you attended the Progra Director breakout session)	am
1:15-2:00 PM: Program Director Breakout Session (leave blank if you attended t fellow networking breakout session)	he
2:00-2:30 PM: The Evolution of BPCA Legislation (Lisa Kaeser)	
4:10-4:55 PM: Special Topic COVID-19 Presentation (Roberta DiBiasi, Sarah Mull	кеу

#### Agenda Feedback

Please provide your feedback on the following sessions on September 1:

2:05-2:45 PM: What No One Ever Tells You About Scientific Publishing (John Wagner)

3:40-4:20 PM: Strategies to Optimize Career Development During the COVID-19 Pandemic (Dean Sheppard)

#### Agenda Feedback

**Fellow Presentations and Collaborations** 

Please provide your feedback on the fellow presentations. What are your thoughts on the new structure for the fellow presentations?

Presenting Fellows Only: Please provide your feedback on the scoring criteria used to select the top 3 abstracts for presentation to the entire group? Were the scoring criteria helpful?

Please provide your feedback on the site collaboration sessions. What suggestions do you have to improve communications across sites and continue momentum from the meeting discussions?

# Best Pharmaceuticals for Children Act NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development

#### **General Feedback**

On a scale of 1 to 5, with 5 being the best, what is your overall rating of the Ninth Annual Meeting of T32 Trainees?



What do you recommend we change for next year's meeting? Include any new topics you'd like to see presented.